3-chloro-2,5-dimethylthiophene | 17249-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-chloro-2,5-dimethylthiophene
• CAS: 17249-81-9
• 化学式: C₆H₇ClS
• 分子量: 146.641
• InChiKey: PHGYDZAYLOPRSV-UHFFFAOYSA-N

物化性质

• 沸点：
  181.1±35.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-2,5-dimethylthiophene 在 sodium carbonate 作用下， 以 水 、 乙酸乙酯 、 三氟乙酸 为溶剂， 反应 0.2h， 生成
  参考文献：
  名称：

  In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents

  摘要：

  一种基于老鼠的检测方法（SmartCube）被用于一种新型抗精神病药物的筛选和首选优化。

  DOI：

  10.1039/c6md00128a
• 作为产物：
  描述：

  2,5-二甲基噻吩 在 N-氯代丁二酰亚胺 作用下， 以 溶剂黄146 为溶剂， 以50%的产率得到3-chloro-2,5-dimethylthiophene
  参考文献：
  名称：

  In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents

  摘要：

  一种基于老鼠的检测方法（SmartCube）被用于一种新型抗精神病药物的筛选和首选优化。

  DOI：

  10.1039/c6md00128a

文献信息

• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET PROCÉDÉ D'UTILISATION CORRESPONDANT
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2013119895A1

  公开（公告）日：2013-08-15

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。本文提供的化合物可用于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症。
• [EN] NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE RÉCEPTEUR DE SPHINGOSINE 1-PHOSPHATE
  申请人：SWENSON ROLF ERIC

  公开号：WO2014158302A1

  公开（公告）日：2014-10-02

  The present invention relates to sphingosine-1 -phosphate (S1 P) receptors and compounds of the general formula (1), that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1 -phosphate receptor 2 (S1 P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1 P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1 P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

  本发明涉及鞘氨醇-1-磷酸（S1P）受体和一般式（1）的化合物，这些化合物在与这些受体相关的疾病的治疗和预防中是有用的。更具体地，本发明涉及合成和使用鞘氨醇-1-磷酸受体2（S1P2）拮抗剂，这些拮抗剂在癌症、动脉粥样硬化、糖尿病视网膜病变和其他炎症性疾病的治疗中是有用的。这些炎症性疾病中可以用这些S1P2拮抗剂治疗的包括以纤维化为特征的疾病，如慢性肺病、慢性肾脏和肝脏疾病、慢性心脏病，以及硬化/硬皮病等皮肤病。S1P2拮抗剂还可用于治疗多形性胶质母细胞瘤（脑癌）、儿童神经母细胞瘤和其他癌症。
• Process for the preparation of a borylated thiophene
  申请人：Smith R. Milton

  公开号：US20080091035A1

  公开（公告）日：2008-04-17

  Borylated thiophenes are prepared by the process. The borylated thiophenes are intermediates to thiophene polymers for electronic applications.

  Borylated thiophenes通过该过程制备。Borylated thiophenes是用于电子应用的噻吩聚合物的中间体。
• PLATELET ADP RECEPTOR INHIBITORS
  申请人：Scarborough Robert M.

  公开号：US20120149688A1

  公开（公告）日：2012-06-14

  Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  式(I)和(VIII)的新化合物，其中更特别地包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰基胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，它们是有效的血小板ADP受体抑制剂。这些衍生物可用于各种药物组合物中，特别是对于预防和/或治疗心血管疾病，特别是与血栓形成相关的疾病非常有效。本发明还涉及一种用于预防或治疗哺乳动物中的血栓形成的方法，包括给予化合物(I)到(VIII)的治疗有效量或其药学上可接受的盐。
• GLUCOPYRANOSIDE COMPOUND
  申请人：NOMURA Sumihiro

  公开号：US20120258913A1

  公开（公告）日：2012-10-11

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式：其中环A和环B是：(1) 环A是一个可选取代的不饱和单环杂环，环B是一个可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，(2) 环A是一个可选取代的苯环，环B是一个可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或(3) 环A是一个可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是一个碳原子或氮原子；Y是—(CH2)n—(n为1或2)；或其药学上可接受的盐或前药。